Last reviewed · How we verify

NCT06707714: Metabolomics

A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome After Radical Gastrectomy

ENROLLING BY INVITATION Last updated 27 November 2024
What this trial tests

trial testing hypertension in Metabolic Syndrome in 150 participants. Enrolling by invitation.

Timeline
1 July 2023
Primary endpoint
1 July 2026
1 July 2026

Quick facts

Lead sponsorDong Peng
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment150
Start date1 July 2023
Primary completion1 July 2026
Estimated completion1 July 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Dong Peng

Who can join

18 and older, any sex, with Metabolic Syndrome or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Analysis of preoperative and postoperative metabolite changes: Through metabolomics technology, the changes of preoperative and postoperative metabolites in patients with gastric cancer complicated with metabolic syndrome were systematically analyzed, and the key metabolites related to the remission of hypertension, hyperlipidemia, and diabetes after surgery were found. 2. Explore the influencing factors of postoperative remission of metabolic syndrome: Combined with clinical data, the association between various metabolites and the degree of postoperative remission was evaluated, and the main factors affecting postoperative remission were determined. 3. Reveal the mechanism of postoperative remission of metabolic syndrome: through multi-level metabolomics analysis, to clarify the metabolic pathways and mechanisms involved in the process of postoperative remission, and provide a new theoretical basis for the development of tumor metabolic surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of hypertension

Trials testing the same drug.

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

Other Dong Peng trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing